Sexual Side Effects of Antidepressants: An Honest Discussion

You finally feel better, and then you notice that sex has changed. SSRI sexual side effects, such as lower desire or trouble reaching orgasm, are common, and a 2019 review calls them one of the most frequent reasons people drop out of antidepressant treatment. Many people never tell the person prescribing the medication.

This post covers how often it happens, which antidepressants seem to affect it less, how good the evidence is for each fix, and symptoms that last after stopping. Common SSRI side effects covers the wider list.

What It Can Look Like

The FDA label for sertraline says SSRIs may cause delayed or failed ejaculation, lower desire and erectile dysfunction in men, and lower desire and delayed or absent orgasm in women. The label for venlafaxine, an SNRI, lists the same effects. This much is well established. Some people also notice less lubrication.

How Common Is It, Honestly?

There’s no single honest number, because the answer depends heavily on how the question is asked:

• When people have to volunteer it. In trials of vortioxetine (Trintellix), about 3% to 5% of men and 2% or fewer of women reported a sexual side effect on their own.
• When they’re asked with a questionnaire. In the same label, new sexual problems showed up in 16% to 34% of people on the medication, depending on sex and dose. They also showed up in 14% to 20% of people on placebo.
• In a large U.S. survey. Among 6,297 primary care patients, rates with SSRIs and extended-release venlafaxine were 36% to 43%. In a subgroup unlikely to have other reasons for sexual problems, rates across antidepressants were 7% to 30%. This was a one-time survey, so it shows how common the problems were, not what each medication caused.
• In a pooled analysis of studies that asked directly. Rates ranged from about 26% to 80% among antidepressants that raised rates above placebo, though the authors note that including open-label studies could weaken these findings.

It’s common, it’s far more common when someone asks, and not all of it comes from the medication, as those placebo numbers show.

Why So Few People Bring It Up

Embarrassment is one documented reason, and it isn’t only on the patient’s side. The vortioxetine label says these effects are underreported partly because patients and physicians may be reluctant to discuss them. In the U.S. survey above, physicians consistently underestimated how common they were, and the 2019 review says clinicians rarely bring the topic up as routine.

FDA labels tell prescribers to ask, before starting and during treatment, because people may not mention it on their own. If nobody has asked you, that isn’t a sign it doesn’t matter.

Is It the Medication, the Depression, or Something Else?

The sertraline label notes that changes in desire, performance and satisfaction often come with the psychiatric condition itself. Research also links depression and sexual problems in both directions: each raises the risk of the other.

Timing is the most useful clue, and labels ask prescribers to take a detailed history that includes when symptoms began. A problem that started during the depression points one way. A problem that started after the medication or a dose increase, while your mood was improving, points the other.

Other causes are possible too, so it can be worth checking with your primary care provider. Our post on perimenopause touches on hormones. Our providers don’t prescribe hormonal treatments such as birth control or hormone therapy, so your gynecologist or primary care provider is the right person to ask about those.

Which Antidepressants Affect This Less?

Bupropion comes out low fairly consistently. In the U.S. survey, its rates were 22% to 25%, and in the pooled analysis it didn’t differ significantly from placebo. Mirtazapine’s rates were lower than SSRIs’ in most studies, though one large survey disagreed. The same analysis, a Spanish study of 1,022 patients and a 2026 Danish study of men looked favorable, yet the U.S. survey placed it with the higher group.

Ranking the SSRIs against each other isn’t settled. The pooled analysis put sertraline highest, while a network meta-analysis found escitalopram and paroxetine higher than some others, rated its overall evidence as low and said it couldn’t give a precise estimate for any one medication. In the Danish study, an international study of men starting one of four antidepressants, venlafaxine (an SNRI) had the highest risk of a recorded sexual problem, while sertraline didn’t differ from citalopram.

What Can Help

The evidence here is thinner than most people expect. A Cochrane review found 23 trials with 1,886 people, most options tested only once, and called the evidence “rather limited.” A later U.S. review of 57 trials found that 70% of open-label trials reported success, compared with 22% of placebo-controlled ones. Think of each option as something to try, not a promise.

• Waiting. This is reasonable for a short while, but don’t count on it. The 2019 review says some people improve within weeks or months, but results vary by study. In a 1997 Spanish study of 344 people taking SSRIs, about 81% saw no improvement at all after six months. In a small 2004 international study from Austria of 26 people with delayed orgasm, about 30% recovered completely within six months, more often when the problem was mild to moderate. In a U.S. study that interviewed people about three months after starting an SSRI, 83% of those with this side effect still had it.
• Lowering the dose. These effects may be dose-related, so a lower dose can be an option if it still controls your symptoms. It’s generally considered only after your symptoms have fully gone away and treatment has continued for a while, and only with your provider. The change isn’t immediate, and it carries a risk to your mental health: a lower dose can bring symptoms back, raise anxiety or cause withdrawal symptoms.
• Switching. The 2019 review lists switching to bupropion (or mirtazapine) as an option and points to one controlled study of switching from fluoxetine to bupropion, but the support rests mainly on observational studies and clinical experience. Randomized evidence for switching is very limited: the Cochrane review, as of 2013, found no randomized trials of switching to antidepressants currently available. An eight-week randomized study described in the vortioxetine label found more sexual improvement after switching to vortioxetine than to escitalopram. Switching can bring new side effects or a return of symptoms.
• Adding a medication. Using bupropion, sildenafil or tadalafil this way is off-label: none is FDA-approved to treat antidepressant sexual side effects. Adding bupropion, at the higher of the two amounts studied, helped in studies of both men and women, per Cochrane; the lower amount didn’t. Cochrane calls it the most promising option studied so far for women. For men with erectile problems, adding sildenafil or tadalafil appears effective. Sildenafil has less evidence in women: Cochrane couldn’t say whether it works better than placebo, one trial of 98 women found a benefit, and the Viagra label says it isn’t for use in women. If this is an option for you, your provider can tell you whether they prescribe it or whether your primary care provider or a urologist is the better person to ask. Sildenafil must not be taken with nitrate medicines, because together they can make blood pressure drop suddenly to a dangerous, unsafe level, so share your full medication list.
• A planned break from the medication. A small 1995 study of 30 people found improvement with sertraline and paroxetine but not fluoxetine. The Cochrane review, as of 2013, found no randomized trials. Since then, a small international trial in Iran randomly assigned 63 men taking SSRIs other than fluoxetine to skip their weekend doses or keep taking them as usual. Sexual function improved with the break, but everyone knew which group they were in, and 50 men finished. The 2019 review warns that stopping, even briefly, can bring relapse or withdrawal symptoms. This is only ever something to plan with your provider, never on your own. Please don’t stop a medication on your own; some can cause withdrawal symptoms or a return of symptoms if stopped suddenly.
• Simple steps. Vaginal lubricants are one suggestion in the 2019 review for dryness. In a lab study of 47 women, exercise shortly beforehand increased physical arousal, measured in the lab rather than in daily life.

Please don’t stop a medication on your own; some can cause withdrawal symptoms or a return of symptoms if stopped suddenly. If this side effect is making you think about stopping, that’s exactly the thing to say out loud.

When Symptoms Last After Stopping

Some people report sexual problems that continue after the antidepressant is gone. This is called post-SSRI sexual dysfunction, or PSSD. Reported symptoms include genital numbness, weak or pleasureless orgasm, low desire and erectile problems. PSSD is debated, mainly over how often it happens and what causes it.

On one side, there are published case series, though those 300 cases came from a reporting website. Researchers have proposed diagnostic criteria. Europe’s medicines regulator recommended a warning about long-lasting symptoms. An Israeli records study estimated a risk of about 1 in 216 men, and its authors think that may be an undercount.

On the other side, that estimate rests on just four men and looked only at erectile problems. Health Canada added a warning about reports of these symptoms, but said it could neither confirm nor rule out a causal link. A 2018 literature review says the prevalence is unknown, that diagnosis means ruling out other causes, and that there’s no definitive treatment. So it appears uncommon, but nobody has a firm number.

The fluoxetine (Prozac) label says symptoms “occasionally persist” after stopping, while the current sertraline, escitalopram and venlafaxine labels (checked November 8, 2026) don’t say this. A petition asked the FDA to require a warning across SSRIs and SNRIs, and Public Citizen sued in 2024 because the agency hadn’t decided. As of November 8, 2026, the FDA had not announced a decision.

If this is happening to you, it deserves to be taken seriously. Tell a provider what changed and when, and ask about other causes. If you’re deciding whether to start a medication, it’s fair to weigh this uncertainty alongside the risks of leaving depression untreated. Our post on the risks and benefits of psychiatric medication can help with that.

Bringing It Up

One sentence is enough: “I’m having sexual side effects, and I want to know what my options are.” You don’t have to share details you’d rather keep private. Saying it’s affecting whether you want to stay on the medication gives your provider plenty to work with.

Before that conversation, it helps to think about what changed, roughly when it started and whether it was already a problem before the medication. Then ask about the trade-offs: what a lower dose or a switch could cost you, and whether adding something or trying a simple step makes sense first. It’s also worth asking about sexual side effects after treatment ends, not just during it, so anything that lingers gets noticed.

For adults in Mount Laurel and across New Jersey, medication management with our board-certified psychiatric nurse practitioners includes regular follow-ups where this can be on the agenda. Our depression guide covers the bigger picture of treatment.

Frequently Asked Questions

Do SSRI sexual side effects go away on their own?

Sometimes, but usually not. Results vary by study: in one Spanish study, about 81% of people saw no improvement after six months, while a small 2004 international study from Austria found that about 30% of people with delayed orgasm recovered completely in that time. It’s reasonable to raise it early rather than wait.

Which antidepressant has the fewest sexual side effects?

Bupropion has fairly consistent evidence for lower rates, though not zero. Mirtazapine’s rates were lower than SSRIs’ in most studies, though one large survey disagreed. No antidepressant suits everyone: the bupropion label warns about seizure risk, for example. Your provider can weigh this against your symptoms and history.

Can I skip doses to improve my sex life?

Please don’t try this on your own. Evidence for planned breaks is limited to small studies, and some medications can cause withdrawal symptoms or a return of symptoms if stopped suddenly. Talk with your provider first.

Is PSSD real?

People do report lasting symptoms, and regulators in Europe and Canada have added warnings about those reports. In October 2026, the UK’s medicines regulator (MHRA) said leaflets for certain antidepressants will be updated to name PSSD, and also said that, when antidepressants are used appropriately under clinical supervision, the benefits outweigh the risks for the vast majority of people. What’s debated is how often it happens and how much is caused by the medication. Health Canada said it could neither confirm nor rule out a causal link. If you have symptoms after stopping, tell a provider.

If sexual side effects are making you question your treatment, medication management gives you regular follow-ups to adjust the plan, and a psychiatric evaluation is a good place to begin if you’re new to care.

This article is for general educational purposes only. It does not constitute medical advice, does not establish a provider-patient relationship, and is not a substitute for individual evaluation, diagnosis, or treatment by a qualified clinician. If you’re in crisis or thinking about harming yourself, call or text 988 (Suicide & Crisis Lifeline), any time, day or night. In an emergency, call 911 or go to the nearest emergency room.